These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20929391)

  • 1. Short communication: contribution of the immunovirological state and traditional cardiovascular risk factors to low HDL-cholesterol in HIV patients.
    Palacios R; Puerta S; Orihuela F; Olalla J; Roldán J; Grana M; Márquez M; Colmenero JD; Santos J;
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1167-70. PubMed ID: 20929391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition.
    Bernal E; Masiá M; Padilla S; Gutiérrez F
    AIDS Patient Care STDS; 2008 Jul; 22(7):569-75. PubMed ID: 18479224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
    Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
    AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection.
    Guimarães MM; Greco DB; Figueiredo SM; Fóscolo RB; Oliveira AR; Machado LJ
    Atherosclerosis; 2008 Dec; 201(2):434-9. PubMed ID: 18359028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
    Muhammad S; Sani MU; Okeahialam BN
    Ann Afr Med; 2013; 12(1):24-8. PubMed ID: 23480991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain.
    Estrada V; Bernardino JI; Masiá M; Iribarren JA; Ortega A; Lozano F; Miralles C; Olalla J; Santos J; Elías MJ; Domingo P; Cruz AF
    HIV Clin Trials; 2015; 16(2):57-65. PubMed ID: 25874992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients.
    Badiou S; Thiebaut R; Aurillac-Lavignolle V; Dabis F; Laporte F; Cristol JP; Mercie P;
    J Infect; 2008 Jul; 57(1):47-54. PubMed ID: 18554723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycaemic profile changes by highly active antiretroviral therapy in human immunodeficiency virus-infected patients.
    Duro M; Rebelo I; Barreira S; Sarmento-Castro R; Medeiros R; Almeida C
    Int J STD AIDS; 2015 Oct; 26(11):796-802. PubMed ID: 25281540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
    Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
    AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
    Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
    HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital.
    Julius H; Basu D; Ricci E; Wing J; Basu JK; Pocaterra D; Bonfanti P
    Curr HIV Res; 2011 Jun; 9(4):247-52. PubMed ID: 21631427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ferritin in HIV-positive patients is related to immune deficiency and inflammatory activity.
    López-Calderón C; Palacios R; Cobo A; Nuño E; Ruiz J; Márquez M; Santos J
    Int J STD AIDS; 2015 May; 26(6):393-7. PubMed ID: 24912540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.
    Zhang S; van Sighem A; Kesselring A; Gras L; Prins JM; Hassink E; Kauffmann R; Richter C; de Wolf F; Reiss P;
    HIV Med; 2015 May; 16(5):265-72. PubMed ID: 25604160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and factors associated with erectile dysfunction in a cohort of HIV-infected patients.
    Pérez I; Moreno T; Navarro F; Santos J; Palacios R
    Int J STD AIDS; 2013 Sep; 24(9):712-5. PubMed ID: 23970586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.